Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

Efficiency of IgM Anti-Cardiolipin Serum Level Screening for Monitoring Response to Anti-Tuberculosis Treatment in Comparison with Sputum Smear Conversion Test

Hamidreza Kouhpayeh 1 , Abbass-Ali Niazi 2 , * and Reza Karimian 3
Authors Information
1 Infectious Diseases Department, Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran
2 Pathology Department, Zahedan University of Medical Sciences, Zahedan, Iran
3 Infectious Diseases Department, Zahedan University of Medical Sciences, Zahedan, Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: March 2018, 20 (3); e57134
  • Published Online: February 28, 2018
  • Article Type: Research Article
  • Received: June 28, 2017
  • Revised: October 28, 2017
  • Accepted: February 20, 2018
  • DOI: 10.5812/zjrms.57134

To Cite: Kouhpayeh H, Niazi A, Karimian R. Efficiency of IgM Anti-Cardiolipin Serum Level Screening for Monitoring Response to Anti-Tuberculosis Treatment in Comparison with Sputum Smear Conversion Test, Zahedan J Res Med Sci. 2018 ; 20(3):e57134. doi: 10.5812/zjrms.57134.

Abstract
Copyright © 2018, Zahedan Journal of Research in Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Longo D, Fauci AS, Kasper D, Hauser SL. Harrison's principles of internal medicine. 19th ed. New York: Mc Graw-Hill; 2015.
  • 2. Ministry of Health & Medical Education . Center for Disease Control. TB situation in Iran; 2016. Available from: tb-lep.behdasht.gov.ir/TB_Situation_in_Iran.aspx.
  • 3. World Health Organization . Global tuberculosis report. 2016. Available from: http://www.who.int/tb/publications/global_report/g.tbr2016_executive_summary.pdf?ua=1.
  • 4. Coban AY, Cihan CC, Bilgin K, Uzun M, Akgunes A, Cetinkaya E, et al. Blood agar for susceptibility testing of Mycobacterium tuberculosis against first-line drugs. Int J Tuberc Lung Dis. 2006;10(4):450-3. [PubMed: 16602412].
  • 5. World Health Organization . . Treatment of tuberculosis: Guidelines for treatment of drug-susceptible tuberculosis and patient care. fourth ed. Geneve, Switzerland: WHO Press; 2017.
  • 6. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, et al. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis. 2009;9:15. doi: 10.1186/1471-2334-9-15. [PubMed: 19208218].
  • 7. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem. 1995;64:29-63. doi: 10.1146/annurev.bi.64.070195.000333. [PubMed: 7574484].
  • 8. Jacobsen M, Mattow J, Repsilber D, Kaufmann SH. Novel strategies to identify biomarkers in tuberculosis. Biol Chem. 2008;389(5):487-95. doi: 10.1515/BC.2008.053. [PubMed: 18953715].
  • 9. Hardy RR. B-1 B cell development. J Immunol. 2006;177(5):2749-54. doi: 10.4049/jimmunol.177.5.2749. [PubMed: 16920907].
  • 10. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol. 2011;11(1):34-46. doi: 10.1038/nri2901. [PubMed: 21151033].
  • 11. Converse PJ, Dannenberg AJ, Estep JE, Sugisaki K, Abe Y, Schofield BH, et al. Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect Immun. 1996;64(11):4776-87. [PubMed: 8890239].
  • 12. Dannenberg AJ. Liquefaction and cavity formation in pulmonary TB: a simple method in rabbit skin to test inhibitors. Tuberculosis (Edinb). 2009;89(4):243-7. doi: 10.1016/j.tube.2009.05.006. [PubMed: 19559651].
  • 13. Goodridge A, Cueva C, Lahiff M, Muzanye G, Johnson JL, Nahid P, et al. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. Tuberculosis (Edinb). 2012;92(3):243-7. doi: 10.1016/j.tube.2012.02.004. [PubMed: 22406155].
  • 14. Kumaresan JA, Ahsan Ali AK, Parkkali LM. Tuberculosis control in Bangladesh: success of the DOTS strategy. Int J Tuberc Lung Dis. 1998;2(12):992-8. [PubMed: 9869115].
  • 15. Nowak D, Radenbach D, Magnussen H. [Chemotherapy of pulmonary tuberculosis. Sputum culture conversion in 8 weeks in 84% of patients]. Dtsch Med Wochenschr. 1987;112(36):1367-70. doi: 10.1055/s-2008-1068252. [PubMed: 3622281].
  • 16. Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. Tuber Lung Dis. 1996;77(2):124-9. doi: 10.1016/S0962-8479(96)90026-X. [PubMed: 8762846].
  • 17. Thorson A, Long NH, Larsson LO. Chest X-ray findings in relation to gender and symptoms: a study of patients with smear positive tuberculosis in Vietnam. Scand J Infect Dis. 2007;39(1):33-7. doi: 10.1080/00365540600951176. [PubMed: 17366010].
  • 18. Goodridge A, Zhang T, Miyata T, Lu S, Riley LW. Antiphospholipid IgM antibody response in acute and chronic Mycobacterium tuberculosis mouse infection model. Clin Respir J. 2014;8(2):137-44. doi: 10.1111/crj.12049. [PubMed: 23910993].
  • 19. Ordonez C, Tarajia M, Rivera R, Sambrano D, Batista V, Chavez M, et al. Total IgM and Anti-Phosphatidylcholine IgM Antibody Secretion Continue After Clearance of Mycobacterium bovis Bacillus Calmette-Guerin Pleural Infection. Lung. 2017;195(4):517-21. doi: 10.1007/s00408-017-0019-0. [PubMed: 28551717].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments